Table 4.

Comparision of overall survival rates

Variable	2-year	5-year	Median (95% CI)	P
	%	%
Overall	36.4	12.6	15.36 (11.14-19.59)
Age
≤65	38.5	19.7	14.56 (6.16-22.96)	0.328
>65	34.0	6.4	15.36 (9.41-21.32)
Sex
Male	33.3	10.6	14.26 (9.58-18.94)	0.074
Female	62.3	27.7	38.00 (5.29-70.70)
KRAS mutation subtype
Non-G12C	37.5	14.8	15.36 (5.01-25.71)	0.201
G12C	35.8	10.9	14.46 (8.34-20.58)
Brain metastasis
No	34.4	13.1	14.40 (9.63-19.16)	0.397
Evet	39.7	11.1	19.16 (10.70-27.62)

Kaplan Meier, Log rank test, P<0.05 was considered statistically significant.